Experts in Polymer Therapeutics
Our founding scientific and management teams have deep experience in polymer drug development. Serina co-founders Harris and Bentley developed the first-generation of PEGylated drugs at Shearwater Polymers. PEG became widely accepted as the standard technology platform for improving biological drugs.
Our Leadership
Former Chief Development Officer, Nektar Therapeutics
Co-Founder, ThromboGenics, Ltd. (now Oxurion)
25 Year Biotechnology Executive (led polymer therapeutics programs for 13 years)
Led $36M+ raise at Serina
VP, Research Group, Shearwater Polymers, and VP, Research Nektar Therapeutics
Fulbright Senior Research Scholar
Fellow, Japan Agency for Science & Technology
Professor and Chairman, Dept of Chemistry University of Maine
Senior executive in the pharma industry for > 20 years
Expert in CMC, drug delivery, pharmacology
Co-inventor on multiple polymer therapeutics patents
Advanced multiple product candidates through IND
Founded Shearwater Polymers, Inc. in 1992
200 publications and 75 patents
2005 Recipient of the Nagai Innovation Award
Member, Swedish Academy of Engineering Sciences
Led $36M+ raise at Serina
Board of Directors & Advisory
Board of Directors
J. Milton Harris, PhD
Founder, Chairman of the Board
Michael Bentley, PhD
Founder, Chief Scientific Officer
Barbara Fisk
Director
James R. Hudson, Jr.
Director
Lonnie S. McMillian
Director Emeritus
Miguel Loya
Director
Randall W. Moreadith, MD, PhD
President, Chief Executive Officer
Clinical Advisory Board
C. Warren Olanow, MD
William K. Schmidt, PhD
Join our revolution
Our scientists are driving the next generation of polymer science. Learn more about our mission to engineer the future of drug delivery.